
Please try another search
SAN RAFAEL, Calif. - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company with a market capitalization of $12.96 billion and impressive gross margins of nearly 80%, announced on Monday...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) recently reported that Erin Burkhart, the company's Group Vice President and Chief Accounting Officer, sold a portion of her holdings in the company....
On Thursday, Citi analysts, led by David Lebowitz, reaffirmed a Neutral rating on shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), maintaining the price target at $82.00. According to...
BioMarin Pharmaceutical Inc (NASDAQ:CRSP) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks hereCRISPR Therapeutics’ loss per share...
BioMarin Pharmaceutical Inc. (NASDAQ:EBS) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Is BMRN going up? Or down? Predict to see...
Sarepta Therapeutics On Monday April 25, 2016 Sarepta Therapeutics (NASDAQ:SRPT) had a FDA advisory panel shoot down its drug Eteplirsen, used to treat patients with Duchenne Muscular Dystrophy --...
Instrument Type
Region
Sector
Industry
Date
Category
Provider